After GH infusion, GH impairs the insulin-elicited suppression of endogenous glucose production, but this effect is not correlated to modifications of hepatic glucose-glucose-6-phosphate cycle activity, which is a marker of insulin resistance in many metabolic disorders. Here, GH1 is linked to metabolic disease.